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HCV prevalence, study perspective, discount rate, screening and
antiviral treatment mode varied. The incremental effectiveness
of HCV screening and early treatment compared to no screen-
ing and standard care varied from 0.0004 LYG to 0.066 LYG
(0.0001–0.072 QALY). Incremental cost-effectiveness ratios
(ICER) of HCV screening versus no screening ranged from
18,300 to €1,151,000/QALY. HCV screening seems to be
cost-effective in populations with high HCV prevalence
(€18,300–46,700/QALY), but is associated with higher ICER in
populations with an average HCV prevalence. CONCLUSIONS:
Based on current evidence, HCV screening and early treatment
has the potential to improve life-expectancy and quality-adjusted
life-expectancy, but should focus on populations with elevated
HCV prevalence in order to be cost-effective. Further research on
the long-term health-economic impact of HCV screening when
combined with appropriate monitoring strategies in different
European health care systems is needed.
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OBJECTIVES: To determine cost-effectiveness and cost-utility of
DAA added to standard care compared to standard care in the
treatment of severe sepsis with MOF from public payer’s per-
spective in Poland. METHODS: Results of a systematic review
of published clinical trials conducted according to Polish HTA
Guidelines were used to assess effectiveness and safety of DAA.
Data on reduction of 28-day all-cause mortality and probability
of adverse events for patients treated with DAA or with standard
treatment reported in this study, baseline mortality of sepsis
patients in Poland, probability of death during four years follow-
ing intensive care and life tables for general population were
incorporated into the decision tree model. A 24-year analytic
horizon was established as life expectancy in general population
of the same age and gender characteristics as sepsis patients.
Epidemiology data were obtained from Polish Sepsis Registry.
Cost-utility analysis was performed using utilities for sepsis
patients and general population—derived from published litera-
ture. Costs of treatment valid from public payer’s perspective
were taken into account. Costs of DAA, intensive care unit
hospitalization, parenteral nutrition, physician consultations,
bleeding and thrombotic events were included. All calculations
were performed for 2007 (1EUR = 3.8PLN). Only effects were
discounted (at 5% rate), as no costs occur beyond 1 year. Sensi-
tivity analysis was conducted assuming range of cost for DAA,
length of ICU stay, length of parenteral nutrition and discount
rate for effects. RESULTS: Adding DAA to standard therapy of
patients with severe sepsis and MOF signiﬁcantly reduces 28-day
mortality. Cost-effectiveness ratios are below the established
thresholds (ICER = 42,517PLN, ICUR = 58,615PLN). Sensitiv-
ity analysis showed that these results are robust. CONCLU-
SIONS: DAA added to conventional treatment of severe sepsis
with two or more organ dysfunctions is cost-effective from polish
public payer’s perspective.
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OBJECTIVES: According to international HIV treatment
guidelines, the goal of highly active antiretroviral treatment
(HAART) is to reduce viral load to undetectable levels (<50
copies/mL). Two therapies have recently been introduced in the
US with similar indications for treatment-experienced patients:
etravirine (TMC125, ETR) and raltegravir (RAL). This analysis
compares the relative cost of each therapy to reach the treat-
ment goal. METHODS: The proportion of patients reaching
undetectable viral load (<50 copies/mL) was reported in the
phase III trials that compared each drug to placebo in the pres-
ence of optimized background regimen (OBR): DUET 1&2
(ETR) and BENCHMRK 1&2 (RAL). No head-to-head trials
comparing ETR and RAL are available, so an indirect compari-
son at week 24 was made. The trials studied similar treatment-
experienced HIV-1 infected patients, but the composition of the
OBR differed. All patients received background darunavir/
ritonavir (DRV/r) in the DUET trials, while less than half
received background DRV/r in the BENCHMRK trials. Sub-
group data from the BENCHMRK trials provided a ‘prior’ esti-
mate of the treatment effect modiﬁcation due to DRV/r use. A
Bayesian analysis was used to adjust for differences in back-
ground DRV/r use between trials. The current analysis esti-
mated the treatment effect assuming that all patients received
background DRV/r. After adjusting for differences in the trials,
efﬁcacy and wholesale acquisition drug costs were analyzed.
RESULTS: The two new agents demonstrate a similar treat-
ment effect when adjusting for differences in OBR. Mean odds
ratios (95% CI) vs. placebo are: ETR 2.08 (1.64–2.6) and RAL
1.92 (0.98–3.42). The annual drug costs are $7957 for ETR
and $9855 for RAL. CONCLUSIONS: Based on the results
showing similar efﬁcacy rates in reaching the treatment goal of
<50 copies/mL, a cost-minimization approach can be taken
when evaluating the addition of ETR or RAL to a HAART
regimen for treatment-experienced patients.
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OBJECTIVES: To test the hypothesis of a reduction in total
medical costs we conducted a cost-study analysis in the setting of
a randomized open-label study comparing an intermittent to a
continuous antiretroviral regimen. METHODS: A total of 403
HIV-1-infected adults who were well tolerating HAART were
randomly assigned to switch to a ﬁxed 8-week off 8-week on
intermittent regimen (IT), or to maintain their current treatment
strategy (CT). The primary end point was the proportion of
patients who reached a CD4 cell count below 300 cells/ml
through 96 weeks. Costs were estimated from the viewpoint of
the payer over the 96-week study period. Resources were costed
from the national reimbursement schedules for hospital in and
out patient admissions and visits and the national selling price for
medications. RESULTS: Complete cost data were available for
391 patients (194 patient in the CT and 197 in the IT arms). The
mean cost per patient over the 96 weeks follow-up (excluding
protocol-driven costs) was €16,162 in the CT arm versus €9738
in the IT arm, a €6424 difference almost entirely due to the
difference in HAART cost. Protocol-driven costs represented
€280 in the CT versus €290 in the IT arm. The use of IT achieved
a 40% reduction in the total cost of HAART. CONCLUSIONS:
Reducing by 40% the cost of HAART medications in a treatment
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